IL1RL1 and acute myeloid leukemia: Taken together, these data showed that anti-Il1rl1 T-BsAb are stable, safe, and exhibit comparable pharmacokinetic to immunoglobulin G (IgG) forms in vitro, and in vivo in normal and AML mice.